Cargando…
BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
BACE1 is the rate-limiting protease in the production of synaptotoxic β-amyloid (Aβ) species and hence one of the prime drug targets for potential therapy of Alzheimer’s disease (AD). However, so far pharmacological BACE1 inhibition failed to rescue the cognitive decline in mild-to-moderate AD patie...
Autores principales: | Peters, Finn, Salihoglu, Hazal, Rodrigues, Eva, Herzog, Etienne, Blume, Tanja, Filser, Severin, Dorostkar, Mario, Shimshek, Derya R., Brose, Nils, Neumann, Ulf, Herms, Jochen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904228/ https://www.ncbi.nlm.nih.gov/pubmed/29327084 http://dx.doi.org/10.1007/s00401-017-1804-9 |
Ejemplares similares
-
Tau deletion reduces plaque‐associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease
por: Peters, Finn, et al.
Publicado: (2019) -
β-secretase inhibition prevents structural spine plasticity deficits in App(NL-G-F) mice
por: Blume, Tanja, et al.
Publicado: (2022) -
BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines
por: Blume, Tanja, et al.
Publicado: (2018) -
In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques
por: Burgold, Steffen, et al.
Publicado: (2014) -
Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model
por: Dorostkar, Mario M., et al.
Publicado: (2014)